Status:
RECRUITING
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Prostate Cancer (Adenocarcinoma)
Eligibility:
MALE
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and ...
Detailed Description
Prostate cancer (PCa) is one of the most common malignancies worldwide in men. Prostate specific membrane antigen (PSMA), as known as folate hydrolase I or glutamate carboxypeptidase II, is overexpres...
Eligibility Criteria
Inclusion
- confirmed treated or untreated prostate cancer patients;
- signed written consent.
Exclusion
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06612580
Start Date
September 1 2024
End Date
December 31 2025
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005